-
Something wrong with this record ?
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma
B. Melichar, Z. Voboril, A. Krajina, E. Malírová, P. Weiner, M. Nová, A. Ryska, J. Dvorák,
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
23225456
Knihovny.cz E-resources
- MeSH
- Hepatic Artery MeSH
- Adult MeSH
- Fluorouracil administration & dosage MeSH
- Infusions, Intra-Arterial MeSH
- Camptothecin administration & dosage analogs & derivatives MeSH
- Colorectal Neoplasms drug therapy pathology MeSH
- Leucovorin administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Liver Neoplasms drug therapy secondary MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
AIM: The aim of the present study was to evaluate single center experience with hepatic arterial infusion (HAI) of irinotecan, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma (CRC). PATIENTS AND METHODS: A retrospective analysis of 68 patients treated between 1998 and 2007 was performed. RESULTS: Among 60 patients who had no simultaneous liver-directed procedure (LDP), the best results obtained were complete response in two patients (3%), partial response in 18 patients (30%), and stable disease in 23 patients (38%), for an overall disease control rate of 72%. Median progression-free survival was 11 months, and median survival was 24 months. Overall survival was significantly better in patients with simultaneous LDP or secondary resection. Steatosis was present in all secondary resection specimens. CONCLUSION: Our data demonstrate the efficacy of HAI of irinotecan combined with 5-fluorouracil and leucovorin for liver metastases from CRC, specifically in patients also treated with LDP.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024068
- 003
- CZ-PrNML
- 005
- 20130711100318.0
- 007
- ta
- 008
- 130703s2012 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)23225456
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacký University Medical School & Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. bohuslav.melichar@fnol.cz
- 245 10
- $a Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma / $c B. Melichar, Z. Voboril, A. Krajina, E. Malírová, P. Weiner, M. Nová, A. Ryska, J. Dvorák,
- 520 9_
- $a AIM: The aim of the present study was to evaluate single center experience with hepatic arterial infusion (HAI) of irinotecan, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma (CRC). PATIENTS AND METHODS: A retrospective analysis of 68 patients treated between 1998 and 2007 was performed. RESULTS: Among 60 patients who had no simultaneous liver-directed procedure (LDP), the best results obtained were complete response in two patients (3%), partial response in 18 patients (30%), and stable disease in 23 patients (38%), for an overall disease control rate of 72%. Median progression-free survival was 11 months, and median survival was 24 months. Overall survival was significantly better in patients with simultaneous LDP or secondary resection. Steatosis was present in all secondary resection specimens. CONCLUSION: Our data demonstrate the efficacy of HAI of irinotecan combined with 5-fluorouracil and leucovorin for liver metastases from CRC, specifically in patients also treated with LDP.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a kamptothecin $x aplikace a dávkování $x analogy a deriváty $7 D002166
- 650 _2
- $a kolorektální nádory $x farmakoterapie $x patologie $7 D015179
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoruracil $x aplikace a dávkování $7 D005472
- 650 _2
- $a arteria hepatica $7 D006499
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intraarteriální infuze $7 D007261
- 650 _2
- $a leukovorin $x aplikace a dávkování $7 D002955
- 650 _2
- $a nádory jater $x farmakoterapie $x sekundární $7 D008113
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Voboril, Zbynek $u -
- 700 1_
- $a Krajina, Antonín $u -
- 700 1_
- $a Malírová, Eva $u -
- 700 1_
- $a Weiner, Pavel $u -
- 700 1_
- $a Nová, Markéta $u -
- 700 1_
- $a Ryska, Ales $u -
- 700 1_
- $a Dvorák, Josef $u -
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 32, č. 12 (2012), s. 5487-93
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23225456 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20130711100742 $b ABA008
- 999 __
- $a ok $b bmc $g 987748 $s 822448
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 32 $c 12 $d 5487-93 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20130703
